{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05093478",
      "orgStudyIdInfo": {
        "id": "HSC-MS-19-0333"
      },
      "organization": {
        "fullName": "The University of Texas Health Science Center, Houston",
        "class": "OTHER"
      },
      "briefTitle": "The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population",
      "officialTitle": "The Prevalence of Local IgE Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-11",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2019-09-10",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-11-30",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2023-11-30",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2021-10-14",
      "studyFirstSubmitQcDate": "2021-10-25",
      "studyFirstPostDateStruct": {
        "date": "2021-10-26",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2024-11-27",
      "resultsFirstSubmitQcDate": "2024-11-27",
      "resultsFirstPostDateStruct": {
        "date": "2024-12-20",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2024-11-27",
      "lastUpdatePostDateStruct": {
        "date": "2024-12-20",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Kunal R. Shetty",
        "investigatorTitle": "Otolaryngology Resident",
        "investigatorAffiliation": "The University of Texas Health Science Center, Houston"
      },
      "leadSponsor": {
        "name": "The University of Texas Health Science Center, Houston",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "American Academy of Otolaryngic Allergy",
          "class": "OTHER"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study to determine the therapeutic response of non-allergic rhinitis patients that have been subtyped as non-allergic rhinitis with local IgE elevation or non-allergic rhinopathy to intranasal capsaicin based on visual analog scale and optical rhinometry, to determine the prevalence of non-allergic rhinitis with local IgE elevation in this study's cohort of patients with non-allergic rhinitis identified by rhinitis history and negative skin testing for allergic rhinitis, and to determine the change, if any, in intranasal IgE levels after capsaicin treatment."
    },
    "conditionsModule": {
      "conditions": [
        "Non-allergic Rhinitis"
      ],
      "keywords": [
        "rhinorrhea",
        "congestion",
        "sneezing",
        "itching"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 28,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Treatment",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: Intranasal capsaicin",
            "Drug: topical lidocaine"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Intranasal capsaicin",
          "description": "Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.",
          "armGroupLabels": [
            "Treatment"
          ]
        },
        {
          "type": "DRUG",
          "name": "topical lidocaine",
          "description": "The nose will be pre-treated with topical lidocaine 15 minutes before each application",
          "armGroupLabels": [
            "Treatment"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "baseline"
        },
        {
          "measure": "Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "4 weeks post treatment"
        },
        {
          "measure": "Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "12 weeks post treatment"
        },
        {
          "measure": "Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "baseline"
        },
        {
          "measure": "Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "4 weeks post treatment"
        },
        {
          "measure": "Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "12 weeks post treatment"
        },
        {
          "measure": "Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "baseline"
        },
        {
          "measure": "Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "4 weeks post treatment"
        },
        {
          "measure": "Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "12 weeks post treatment"
        },
        {
          "measure": "Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "baseline"
        },
        {
          "measure": "Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "4 weeks post treatment"
        },
        {
          "measure": "Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "timeFrame": "12 weeks post treatment"
        },
        {
          "measure": "Change in Maximum Optical Density Determined Via Optical Rhinometry",
          "description": "Optical rhinometry provides continuous measurement of blood flow in nasal vessels (via optical density measurements), which serves as an indirect assessment of nasal congestion. A greater decrease in optical density (OD) from baseline indicates less nasal blood flow and decreased congestion relative to baseline.",
          "timeFrame": "baseline, immediately post first treatment on Day 1"
        },
        {
          "measure": "Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.",
          "timeFrame": "baseline"
        },
        {
          "measure": "Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.",
          "timeFrame": "4 weeks post treatment"
        },
        {
          "measure": "Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.",
          "timeFrame": "12 weeks post treatment"
        },
        {
          "measure": "Maximum Optical Density Determined Via Optical Rhinometry",
          "timeFrame": "12 weeks post treatment"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change in Local Immunoglobulin E (IgE) Level",
          "description": "The IgE levels will be obtained from the brush biopsy of the inferior turbinates. Change from baseline in local Immunoglobulin E (IgE) level after 12 weeks post treatment. Data reported is the 12 weeks post treatment value minus the baseline value.",
          "timeFrame": "baseline, 12 weeks post treatment"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Chronic rhinitis\n\nExclusion Criteria:\n\n* Active smoker\n* Anatomic source of nasal symptoms\n* Chronic rhinosinusitis or other nasal infection\n* History of sinonasal malignancy\n* Pregnancy or lactation\n* Use of medication affecting nasal function (topical steroids, topical anticholinergics, oral antihistamines) in the previous 4 weeks\n* Use or abuse of nasal decongestants.\n* Positive skin prick test for allergic rhinitis",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Kunal R Shetty, MD",
          "affiliation": "The University of Texas Health Science Center, Houston",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "The University of Texas Health Science Center at Houston",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "Treatment",
          "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "28"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "24"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "4"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Treatment",
          "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "28"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "populationDescription": "Age was not collected from one participant in the treatment arm.",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "27"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "62.59",
                      "spread": "16.96"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "28"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "15"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "13"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race and Ethnicity Not Collected",
          "populationDescription": "Race and Ethnicity were not collected from any participant.",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "United States",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "BG000",
                      "value": "28"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "28"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "baseline",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6.07",
                      "spread": "2.41"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "4 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.89",
                      "spread": "2.04"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "12 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "24"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3.75",
                      "spread": "3.15"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "baseline",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "5.57",
                      "spread": "2.80"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "4 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.46",
                      "spread": "2.13"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "12 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "24"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.75",
                      "spread": "2.13"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "baseline",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.25",
                      "spread": "2.60"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "4 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.50",
                      "spread": "1.95"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "12 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "24"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.20",
                      "spread": "1.84"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "baseline",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3.03",
                      "spread": "2.47"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "4 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.71",
                      "spread": "2.07"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "12 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "24"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.29",
                      "spread": "2.91"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Change in Maximum Optical Density Determined Via Optical Rhinometry",
          "description": "Optical rhinometry provides continuous measurement of blood flow in nasal vessels (via optical density measurements), which serves as an indirect assessment of nasal congestion. A greater decrease in optical density (OD) from baseline indicates less nasal blood flow and decreased congestion relative to baseline.",
          "populationDescription": "Data were not collected for 6 participants in the treatment arm.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "log ratio of light in to light out (OD)",
          "timeFrame": "baseline, immediately post first treatment on Day 1",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "22"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0.36",
                      "spread": "0.18"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at Baseline",
          "description": "Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "baseline",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "16.92",
                      "spread": "7.03"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment",
          "description": "Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "4 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "28"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "8.57",
                      "spread": "6.69"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment",
          "description": "Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "12 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "24"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "10",
                      "spread": "7.78"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Change in Local Immunoglobulin E (IgE) Level",
          "description": "The IgE levels will be obtained from the brush biopsy of the inferior turbinates. Change from baseline in local Immunoglobulin E (IgE) level after 12 weeks post treatment. Data reported is the 12 weeks post treatment value minus the baseline value.",
          "populationDescription": "Data were not collected for 5 participants in the Treatment arm.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "kU/L",
          "timeFrame": "baseline, 12 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0.17",
                      "spread": "1.57"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Maximum Optical Density Determined Via Optical Rhinometry",
          "populationDescription": "Data were not collected for this outcome measure.",
          "reportingStatus": "POSTED",
          "timeFrame": "12 weeks post treatment",
          "groups": [
            {
              "id": "OG000",
              "title": "Treatment",
              "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "12 weeks",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Treatment",
          "description": "Intranasal capsaicin: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.\n\ntopical lidocaine: The nose will be pre-treated with topical lidocaine 15 minutes before each application",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 28,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 28,
          "otherNumAffected": 0,
          "otherNumAtRisk": 28
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": true
      },
      "pointOfContact": {
        "title": "Kunal R Shetty, MD",
        "organization": "The University of Texas Health Science Center at Houston",
        "email": "Kunal.R.Shetty@uth.tmc.edu",
        "phone": "713-486-5000"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2022-05-25",
          "uploadDate": "2024-11-18T12:35",
          "filename": "Prot_SAP_000.pdf",
          "size": 490083
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003139",
          "term": "Common Cold"
        },
        {
          "id": "D000086722",
          "term": "Rhinorrhea"
        },
        {
          "id": "D012912",
          "term": "Sneezing"
        },
        {
          "id": "D011537",
          "term": "Pruritus"
        }
      ],
      "ancestors": [
        {
          "id": "D012141",
          "term": "Respiratory Tract Infections"
        },
        {
          "id": "D007239",
          "term": "Infections"
        },
        {
          "id": "D010850",
          "term": "Picornaviridae Infections"
        },
        {
          "id": "D012327",
          "term": "RNA Virus Infections"
        },
        {
          "id": "D014777",
          "term": "Virus Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012818",
          "term": "Signs and Symptoms, Respiratory"
        },
        {
          "id": "D012816",
          "term": "Signs and Symptoms"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D012877",
          "term": "Skin Manifestations"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D008012",
          "term": "Lidocaine"
        }
      ],
      "ancestors": [
        {
          "id": "D000083",
          "term": "Acetanilides"
        },
        {
          "id": "D000813",
          "term": "Anilides"
        },
        {
          "id": "D000577",
          "term": "Amides"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        },
        {
          "id": "D000814",
          "term": "Aniline Compounds"
        },
        {
          "id": "D000588",
          "term": "Amines"
        }
      ]
    }
  },
  "hasResults": true
}